Int J Clin Pharm Th
-
Int J Clin Pharm Th · Jul 2013
Randomized Controlled TrialThe effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis.
Current pharmacotherapy for allergic rhinitis (AR) does not totally ameliorate all symptoms for all patients. Residual symptoms could be due to nasal neuronal hyperresponsiveness caused by stimulation of the ion channel transient receptor potential vanilloid 1 (TRPV1). SB-705498 is a TRPV1 antagonist that has been developed in an intranasal formulation for treatment of AR. ⋯ SB-705498 12 mg for 8 days did not alleviate the allergen-induced symptoms of AR, or provide additional relief of symptoms when in combination with FP. Despite engagement of the TRPV1 receptor there was no translation to clinical efficacy, suggesting redundancy in symptom pathways.
-
Int J Clin Pharm Th · Jul 2013
Comparative StudyPopulation pharmacokinetic study of cyclosporine in the hematopoietic stem cell transplant recipients.
The aim of this study is to investigate the population pharmacokinetics (PopPK) of cyclosporine (CsA) in the Chinese hematopoietic stem cell transplantation (HSCT) recipients for promoting the individualization of CsA administration. ⋯ Body surface area, administration route and postoperative days should be considered in individual pharmacotherapy of cyclosporine for HSCT patient to achieve the desired therapeutic target.